Posted by AGORACOM
at 4:10 AM on Tuesday, March 17th, 2020
VANCOUVER, BC, CANADA (MARCH
17, 2020) – MOTA VENTURES CORP. (CSE: MOTA FSE: 1WZ: GR OTC: PEMTF) (the
“Companyâ€or “Mota
Venturesâ€) an emerging direct to consumer global CBD brand, is
pleased to announce it will be hosting an investor conference call on
Wednesday, March 18, 2020 with Mota Ventures management, Ryan Hoggan, CEO and
Joel Shacker, President to discuss current developments
The call will
be held on Wednesday, March 18th, at 1:15 pm Pacific Time. Media are invited to attend on a listen-only
basis.
Conference
details:
Canada/USA TF:
1-800-319-4610
International
Toll: +1-604-638-5340
Germany TF:
0800-180-1954
Callers should
dial in 5 – 10 min prior to the scheduled start time and simply ask to join the
call.
Conference
replay
Canada/USA TF:
1-800-319-6413
International
Toll: +1-604-638-9010
Replay Access
Code: 4251
About Mota Ventures Corp.
Mota Ventures
is seeking to become a vertically integrated global CBD brand. Its plan is to
cultivate and extract CBD into high-quality value added products from its Latin
American operations and distribute it both domestically and internationally.
Its existing operations in Colombia consist of a 2.5-hectare site that has
optimal year round growing conditions and access to all necessary
infrastructure. Mota Ventures is also seeking to acquire revenue producing CBD
brands and operations in both Europe and North America, with the goal of
establishing an international distribution network for CBD products. Low cost
production, coupled with international, direct to customer, sales channels will
provide the foundation for the success of Mota Ventures.
ON BEHALF OF THEBOARD
OF DIRECTORS
MOTA VENTURES CORP.
Joel Shacker
President
For further information,
readers are encouraged to contact Joel Shacker, President at +604.423.4733 or
by email at [email protected] or www.motaventuresco.com
Neither the Canadian Securities Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this press
release, which has been prepared by management.
COLUMBUS, Ohio -With 9 in 10 Americans favoring legalization of Marijuana for recreation or medicinal purposes and New York weeks away from a decision, aging expert Lisa Cini shares details of marijuana and cannabidiol (CBD) usage among the 11,000+ boomers who responded to her marijuana survey and answered a variety of questions on marijuana consumption, opinion, and usage.
“It’s time to mainstream senior-friendly tools for using marijuana,
and consider implications for designing seniors’ living spaces, or help
those marijuana-using seniors living in multi-generational homes to
partake in designated ways and areas as not to offend family members who
don’t use, including children and grandchildren.â€Tweet this
“I’m not surprised that 83% of the respondents are using some form of
cannabis for recreational and medical reasons. 66% partake daily and
believe that marijuana and/or CBD use is an important component of their
lives,†says Lisa Cini, senior living expert and author of BOOM: The Baby Boomers Guide to Leveraging Technology, so that you can Preserve Your Independent Lifestyle & Thrive. “Don’t
forget that much of the boomer generation grew up smoking weed. Some
never stopped, resumed in retirement, or when they were no longer
raising children. Because the aging process is unforgiving as it relates
to pain, seniors are finding relief from achy bones and joints,
arthritis, sleeplessness, and many other ailments, proving that there’s a
great deal more to marijuana than just getting high, especially for
those battling health and comfort challenges.â€
Seniors are using weed in any number of ways, from smoking to baking
and preparing full meals with cannabutter for many perceived health
benefits including relief from insomnia, anxiety, chronic pain,
depression, muscle tension, arthritis, and migraines in addition to
getting high.
For those who desire CBD without THC, popular brands like vitafusion™
now offer gummy vitamins with full spectrum hemp extract and natural
phytocannabinoids (225mg & 10mg CBD per gummy), Blissful Sleep with
5mg Melatonin (300mg with 10mg CBD per gummy) to induce sleep, and
Chillaxed Mood with natural phytocannabinoids & 10mg L-Theanine (300
mg & 10mg CBD per gummy) to promote calm mental alertness, in
contrast to the restless energy sometimes produced by caffeine. CBD
creams and other skin care products are touted for anti-aging and appeal
to boomers. CBD Anti-Aging Cream with Apple Stem Cells, was voted #1
Best Anti-Aging CBD Skin Cream in 2019 and for those with sensitive
skin, Abinoid Botanicals Face Serum – Blue Chamomile & Hemp was
voted #2 best hemp cream.
“Marijuana and CBD use is a reality that can no longer be ignored, as
it’s very much a part of the daily lives of so many,†adds Cini. “It’s
time to mainstream senior-friendly tools for using marijuana, and
consider implications for designing seniors’ living spaces, or help
those marijuana-using seniors living in multi-generational homes to
partake in designated ways and areas as not to offend family members who
don’t use, including children and grandchildren.â€
Posted by AGORACOM-JC
at 5:22 PM on Monday, March 16th, 2020
SPONSOR: Datametrex AI Limited
(TSX-V: DM) A revenue generating small cap A.I. company that NATO and
Canadian Defence are using to fight fake news & social media
threats. The company announced three $1M contacts in Q3-2019. Click here for more info.
Synthetic media: The real trouble with deepfakes
By M. Mitchell Waldrop
The snapshots above look like people you’d know. Your daughter’s best friend from college, maybe? That guy from human resources at work? The emergency-room doctor who took care of your sprained ankle? One of the kids from down the street?
“Deepfakes play to our weaknesses,†explains Jennifer Kavanagh, a political scientist at the RAND Corporation and coauthor of “Truth Decay,â€
Nope. All of these images are “deepfakes†— the nickname for
computer-generated, photorealistic media created via cutting-edge
artificial intelligence technology. They are just one example of what
this fast-evolving method can do. (You could create synthetic images
yourself at ThisPersonDoesNotExist.com.) Hobbyists, for example, have used the same AI techniques to populate YouTube with a host of startlingly lifelike video spoofs
— the kind that show real people such as Barack Obama or Vladimir Putin
doing or saying goofy things they never did or said, or that revise
famous movie scenes to give actors like Amy Adams or Sharon Stone the
face of Nicolas Cage. All the hobbyists need is a PC with a high-end
graphics chip, and maybe 48 hours of processing time.
It’s good fun, not to mention jaw-droppingly impressive. And coming
down the line are some equally remarkable applications that could make
quick work out of once-painstaking tasks: filling in gaps and scratches
in damaged images or video; turning satellite photos into maps; creating
realistic streetscape videos to train autonomous vehicles; giving a
natural-sounding voice to those who have lost their own; turning
Hollywood actors into their older or younger selves; and much more.
Deepfake artificial-intelligence methods can map the face of, say,
actor Nicolas Cage onto anyone else — in this case, actor Amy Adams in
the film Man of Steel.
Yet this technology has an obvious — and potentially enormous — dark
side. Witness the many denunciations of deepfakes as a menace,
Facebook’s decision in January to ban (some) deepfakes outright and
Twitter’s announcement a month later that it would follow suit.
“Deepfakes play to our weaknesses,†explains Jennifer Kavanagh, a political scientist at the RAND Corporation and coauthor of “Truth Decay,â€
a 2018 RAND report about the diminishing role of facts and data in
public discourse. When we see a doctored video that looks utterly real,
she says, “it’s really hard for our brains to disentangle whether that’s
true or false.†And the internet being what it is, there are any number
of online scammers, partisan zealots, state-sponsored hackers and other
bad actors eager to take advantage of that fact.
“The threat here is not, ‘Oh, we have fake content!’†says Hany
Farid, a computer scientist at the University of California, Berkeley,
and author of an overview of image forensics in the 2019 Annual Review of Vision Science.
Media manipulation has been around forever. “The threat is the
democratization of Hollywood-style technology that can create really
compelling fake content.†It’s photorealism that requires no skill or
effort, he says, coupled with a social-media ecosystem that can spread
that content around the world with a mouse click.
Posted by AGORACOM
at 5:33 PM on Friday, March 13th, 2020
VANCOUVER, BC / March 13, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“)
is excited to announce that for the month of February 2020, its First
Class CBD brand achieved sales of Cdn$2,981,000, with related expenses
for the same time period totaling Cdn$2,814,000. Due to accelerated
marketing efforts in late January 2020, the brand was able to improve
gross margins by 4.9% from January 2020 to February 2020. The Company
anticipates these efforts will yield a further positive impact on
revenue and margin in subsequent months. Sales for February 2019 were
Cdn$320,000; therefore, February 2020 represents an increase of 832%
over the same period last year.
First Class offers a CBD hemp-oil formulation intended to provide
users with the therapeutic benefits that hemp may offer. The hemp oil
used in the products is derived from hemp grown and cultivated in the
United States. The extraction process is designed to maintain all the
beneficial qualities that hemp may offer. First Class offers a range of
products, which include CBD oil drops, CBD gummies, CBD pain relief
cream, CBD skin serum and CBD coffee. The Company plans to continue
growth of First Class in the United States over the balance of 2020, as
well as an expansion into the European market.
“I am extremely pleased with the performance of the First Class brand
through the beginning months of 2020. The continued growth we are
experiencing is evidence of the strong consumer demand in the CBD
market. While eCommerce demand is generally weakest in January and
February, we continue to demonstrate our leadership through achieving
approximately Cdn$5,874,000 in revenue through the first two months of
the year,” stated Ryan Hoggan, CEO of the Company.
The Company cautions that figures for revenue, expenses and margin
generated from the sale of First Class CBD products have not been
audited, and are based on calculations prepared by management. Actual
results may differ from those reported in this release once these
figures have been audited. These figures were translated from US dollar
into Canadian dollar using the Bank of Canada monthly average exchange
rates of 1.3301 for January 2019, 1.3206 for February 2019, 1.3087 for
January 2020 and 1.3286 for February 2020.
About Mota Ventures Corp.
Mota Ventures is seeking to become a vertically integrated global CBD
brand. Its plan is to cultivate and extract CBD into high-quality value
added products from its Latin American operations and distribute it
both domestically and internationally. Mota has established distribution
networks through the acquisition of First Class CBD in the United
States and Sativida in Europe. Mota Ventures is also seeking to acquire
revenue producing CBD brands and operations in both Europe and North
America, with the goal of establishing an international distribution
network for CBD products. Low cost production, coupled with
international, direct to customer, sales channels will provide the
foundation for the success of Mota Ventures.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.
Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com
Posted by AGORACOM-JC
at 4:13 PM on Friday, March 13th, 2020
SPONSOR: Datametrex AI Limited
(TSX-V: DM) A revenue generating small cap A.I. company that NATO and
Canadian Defence are using to fight fake news & social media
threats. The company announced three $1M contacts in Q3-2019. Click here for more info.
As videos faked using artificial intelligence grow increasingly
sophisticated, experts in Switzerland are re-evaluating the risks its
malicious use poses to society – and finding innovative ways to stop the
perpetrators.
In a computer lab on the vast campus of the Swiss Federal Institute
of Technology Lausanne (EPFL), a small team of engineers is
contemplating the image of a smiling, bespectacled man boasting a rosy
complexion and dark curls.
“Yes, that’s a good one,†says lead researcher Touradj Ebrahimi, who
bears a passing resemblance to the man on the screen. The team has
expertly manipulated Ebrahimi’s head shot with an online image of Tesla
founder Elon Musk to create a deepfake – a digital image or
video fabricated through artificial intelligence.
It’s one of many fake illustrations – some more realistic than others – that Ebrahimi’s teamexternal link has created as they develop software, together with cyber security firm Quantum Integrityexternal link (QI), which can detect doctored images, including deepfakes.
Using machine learning, the same process behind the creation of
deepfakes, the software is learning to tell the difference between the
genuine and the forged: a “creator†feeds it fake images, which a
“detector†then tries to find.
“With lots of training, machines can help to detect forgery the same
way a human would,†explains Ebrahimi. “The more it’s used, the better
it becomes.â€
Forged photos and videos have existed since the advent of multimedia.
But AI techniques have only recently allowed forgers to alter faces in a
video or make it appear the person is saying something they never did.
Over the last few years, deepfake technology has spread faster than most
experts anticipated.
The team at EPFL have created the image in the centre by using deep
learning techniques to alter the headshot of Ebrahimi (right) and a
low-resolution image of Elon Musk in profile found on the
Internet.​​​​​​​
(EPFL/MMSPG/swissinfo)
“Precisely because it is moving so fast, we need to map where this
could go – what sectors, groups and countries might be affected,†says
its deputy director, Aengus Collins.
Although much of the problem with malign deepfakes involves their use
in pornography, there is growing urgency to prepare for cases in which
the same techniques are used to manipulate public opinion.
A fast-moving field
When Ebrahimi first began working with QI on detection software three
years ago, deepfakes were not on the radar of most researchers. At the
time, QI’s clients were concerned about doctored pictures of accidents
used in fraudulent car and home insurance claims. By 2019, however,
deepfakes had developed a level of sophistication that the project
decided to dedicate much more time to the issue.
“I am surprised, as I didn’t think [the technology] would move so fast,†says Anthony Sahakian, QI chief executive.
Sahakian has seen firsthand just how far deepfake techniques have
come to achieve realistic results, most recently the swapping of faces
on a passport photo that manages to leave all the document seals intact.
Posted by AGORACOM
at 11:13 PM on Thursday, March 12th, 2020
Vertical Exploration is developing its St. Onge Wollastonite as a soil additive for optimizing marijuana growth. Recently engaged AGRINOVA’s Phase 1 Reseach program also demonstrated Wollastonite can potentially become BNQ certified for agricultural use in Quebec. Recently signed distribution agreement with AREV Brands International to Supply St-Onge Wollastonite to the Cannabis and Hemp Industries. Click Here for More Info.
Definitive
distribution agreement to partner on the sale of Vertical’s
wollastonite from its world-class St-Onge Deposit in place.
Supplying the fast growing cannabis and hemp industries.
Vertical’s high quality Wollastonite has been shown to be beneficial to cannabis plants in a variety of ways
In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium.
The
high-grade St-Onge Wollastonite deposit has pit-constrained mineral
resources of: 7,155,000 tonnes Measured@ 36.20% Wollastonite &
6,926,000 tonnes Indicated@ 37.04%
B.C. Buds Testing Confirmed Wollastonite is critical to marijuana growers
Engaged
AGRINOVA over the past year to conduct research and testing of
Vertical’s St-Onge wollastonite on a range of important agricultural end
uses.
WOLLASTONITE
St-Onge-Wollastonite
Deposit located approximately 90 kilometres Northwest of the city of
Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of
Quebec, Canada.
Research and testing in the Phase 1 program for use in cannabis growth was managed and monitored by AGRINOVA, a highly-regarded Center for Research and Innovation in Agriculture in Quebec
Posted by AGORACOM-JC
at 6:12 PM on Thursday, March 12th, 2020
SPONSOR: CardioComm Solutions (EKG: TSX-V)
– The heartbeat of cardiovascular medicine and telemedicine. Patented
systems enable medical professionals, patients, and other healthcare
professionals, clinics, hospitals and call centres to access and manage
patient information in a secure and reliable environment.
Coronavirus Scare Gives Telehealth an Opening to Redefine Healthcare
With the coronavirus threatening to become a pandemic, health
systems and telehealth vendors see this as an opportunity to bring
connected health to the forefront – and reshape the future of
healthcare.
Most see the exercise as an extension of their preparations for flu
season. Some see this as an opportunity to lobby for telehealth adoption
across the board, saying a possible epidemic offers ample evidence of
the value of telehealth and mHealth.
Defining Telehealth’s Value in a Changing Landscape
“COVID-19 is different because we do not know all the factors
surrounding transmission and its effects on patients,†Jason Hallock,
Chief Medical Officer for SOC Telemed, points out. “Because coronavirus
is new and there have been a significant number of deaths, the
uncertainty surrounding that is scaring both patients and the general
public. Our healthcare workers do not have all the answers
yet. Telehealth providers are challenged to make recommendations when
there are still many unknowns. Telemedicine can be useful to evaluate
and reassure patients in alternative settings, and also can be used to
help patients decide who needs to be seen in the hospital or an
alternative setting like an urgent care.â€
Hallock says telehealth can help by enabling healthcare providers to
treat isolated patients, thus preventing the spread of what has so far
been an extremely contagious virus.
In a Q&A with mHealthIntelligence, Peter Antall, MD,
President and Chief Medical Officer for American Well, offered an
in-depth take on how telehealth might be used.
Q. Telehealth has long been seen as an ideal means of
expediting care during flu outbreaks. How is the coronavirus scare
different? Does this pose any unique challenges that telehealth can
address?
A. The novel coronavirus, or COVID-19, is similar to
influenza in how it is transmitted (airborne), how symptoms manifest
themselves, and the fear it stirs among those individuals at risk. When
evaluating patients through telehealth, we use similar methodology as
that used for influenza, except that the current Centers for Disease
Control and Prevention (CDC) recommendations call for risk
stratification based on known exposure or travel to endemic areas and
referral for testing for those at high risk or those who are sick enough
to need hospital care. Also, unlike with influenza, there are no
current specific treatments, like antivirals, for the coronavirus at
this time.
If local person-to-person spread expands to wide community spread, we
expect care will need to evolve to a method that is quite similar to
how we treat influenza today. Under those circumstances, we will likely
begin diagnosing coronavirus-like illness (CLI) on a clinical basis,
without testing. We would likely then only be expected to refer
inpatients with CLI who need hospital care clinically, while those with
milder symptoms will likely be treated and monitored at home so as to
limit the spread of this disease and not overwhelm our healthcare
facilities.
In this way, telehealth is an ideal venue for an outbreak like this.
We can increase access to care. We can offer care that is commensurate
with the acuity and nature of the symptoms and make referrals as needed.
This helps with infection prevention and control and also allows
patients to receive their care in the home without exposing themselves
to further illness.
One other notable point is the potential for telehealth to help in
providing routine care for other conditions and offset coronavirus fears
in the . Patients have other healthcare needs unrelated to coronavirus,
but many are afraid to go to healthcare settings for fear of catching
disease. This has begun to result in a migration of patients to
telehealth. For example, on February 25, we saw telehealth urgent care
patient volume that was 11 percent higher than expected. Many patients
are now sharing anecdotes indicating they were afraid to sit in a
waiting room, so they used telehealth instead.
Q. Are there new tools or technologies available that can be useful in dealing with the coronavirus?
A. Telehealth itself is a tool in this fight. Keep
in mind that there are many varieties of telehealth. It can be used to
connect a doctor or other provider with a patient in the home via
smartphones or tablets. It can also be used for provider
(specialist)-to-provider consultations in remote areas, for example.
Telehealth carts also exist in healthcare settings and can be used not
only to import care, but also to limit healthcare workers’ exposure to
the virus by using a cart in the isolation room. We see patients
primarily through live video interactions, but we also can fall back to
informed telephone calls, synchronous chatting for therapy and
asynchronous secure messaging for ongoing communications.
The use of symptom trackers and chatbots is another promising area
for coronavirus response. These technologies allow algorithms to be
created and adjusted as more is learned about the coronavirus. These
bots interact with patients and can perform assessments, triage and
ongoing support. The bots can even escalate an interaction to a
telehealth encounter or refer the patient for in-person care.
Finally, home monitoring and medical tricorders are another promising
approach to care. Traditional remote patient monitoring has established
value for managing certain chronic conditions, but the next wave of
home monitoring includes consumer devices like smartwatches (like
the Apple Heart Study), home TVs, and home medical tricorders
like Tytocare that can perform a remote examination. These tools aid
clinicians and patients and provide more robust health data conveniently
from the home setting. Providers can also use the data generated to
better care for the patient or regularly monitor certain conditions.
Q. What must care providers know about telehealth before using it to deal with the coronavirus?
A. Providers must know and understand their role in
this or any other healthcare crisis. They should be well informed and
trained to follow current CDC or World Health Organization guidelines.
They should also understand that telehealth is a powerful tool for
helping fight this outbreak. And they should know that telehealth is a
safe way to treat and/or triage these patients. Whether the provider is a
primary telehealth provider or is not using telehealth today, there is a
real opportunity to participate and play a role in the response.
Providers who have a brick-and-mortar practice should be encouraged
to use telehealth as a triage tool. Providers also need to understand
that during this time, patients with other non-respiratory conditions
also need care. These patients should be afforded a safe way to access
care without risk of infection. Telehealth is also a tool to aid in this
process, as some patients are fearful of going to healthcare facilities
right now. The office-based provider can likewise process other
patients by practicing this way.
Q. What are the barriers or challenges associated with using telehealth to deal with the coronavirus scare?
A. Telehealth visits are typically sufficient to
complete a robust initial assessment. This allow the provider to assign a
risk category, make other diagnoses, or deem the patient as “worried
well.†Some patients may require additional care, as most telehealth in
the home lacks certain medical peripherals that might be needed. Other
reasons for referral would include a high-risk patient who needs to be
tested or a patient who requires escalation of care due to the severity
of their illness. Telehealth visits are generally sufficient for
screening patients, assigning a risk category, answering questions and
recommending the next steps a patient should take.
The barriers to telehealth—such as instances when the patient and
provider do not yet have a relationship—are easily overcome providers
receive similar training around the use of telehealth and as
longitudinal patient records become more available to guide care.
Occasionally the lack of medical peripherals or the inability to touch
the patient during an exam is a barrier, as some patients need hands on
care (e.g., IV, procedures). We have policies that mitigate these
problems in most cases. However, on occasion, a telehealth patient must
be referred for in-person evaluation.
Q. Is there anything that the CDC or any other government
agency can do to support telehealth adoption to deal with the
coronavirus?
A. It is useful for the CDC (and the WHO) to
highlight the important role of telehealth in this outbreak because it
certifies our role within the broader medical community and raises
awareness about this tool.
It would be helpful if the CDC were to make specific recommendations
to telehealth providers that relate to telehealth evaluation of the
coronavirus and associated referrals, coding and monitoring. It would
also be helpful if the CDC were to play a role in advocacy efforts
focused on government reimbursement, particularly in this emergency
situation. Efforts to increase consumer awareness about telehealth as a
safe option for care also could prove essential. When this outbreak
settles down, we would encourage the CDC and HHS to collaborate around
coronavirus standards of care and preparedness so that patients can
expect telehealth providers to be ideally prepared and well-coordinated
for the next outbreak and so that we can offer high-quality care in this
manner to all Americans.
We also believe that our public health system would benefit greatly
from owning its own telehealth network infrastructure. This would allow
the CDC to better scale up, solve for geography and improve
surveillance. It would even allow its public health workers to use
technology to monitor patients under quarantine in the home, saving
themselves travel and limiting healthcare workers’ exposure.
Q. What more can be done with telehealth in the future to
plan for these types of outbreaks, or to perhaps address them before
they become serious?
A. Much needs to be done throughout our country to
better prepare. We need permanent leaders placed at the U.S. Department
of Health and Human Services, the National Institutes for Health, the US
Department of Homeland Security and other key areas, and we need to
reinstate a pandemic-preparedness role at the National Security Council.
We need to fund international efforts to improve screening and research
for emerging diseases, and we need surveillance programs and good
international coordination. We need to fund (not decrease funding) for
our frontline groups, like the CDC, HHS and local public health
services. These are our fighters, and we need them ready and funded
properly as an outbreak like this is a national security issue. We need
stockpiles of materials. Finally, we should be partnering with the
pharmaceutical industry on affordable medications and vaccine research.
Our national telehealth operation today acts like an emergency alert
system. We see cases or potential cases before they are reported. At
American Well, our influenza activity indicator map is more accurate and
more timely than that of the CDC. We already play a meaningful role in
many disease states, including outbreaks. There are still many adoption
and awareness challenges that exist when it comes to telehealth.
Hopefully this unfortunate event will help consumers, providers and
others start to more clearly see how they can and should use telehealth
for future healthcare needs.
Another barrier that we continue to work on is that of reimbursement.
Telehealth is a cost-effective way of receiving care, but it is still
not always a covered benefit by insurance. Most commercial plans are
reimbursing and there is increasing adoption in Medicare Advantage and
Medicaid managed care. But there are still gaps, including a big gap in
fee-for-service coverage for Medicare coverage in the home. Efforts at
reform are underway (see the CONNECT Act), but more work needs to be done so that all Americans can take advantage of this amazing service.
Additionally, with coordination being so important during outbreaks
like this, the simple step of integrating telehealth with other health
information systems, such as EHRs or clinical-decision support, can make
care more seamless and foster better care coordination. This would
speed up access to critical care. Case in point: Consider a scenario
where a patient consults with a physician over a telehealth network and
displays symptoms of COVID-19 while presenting one or more correlating
risk factors. The physician could easily document the experience,
dispatch an alert to a local ED, and ensure precautions are taken by
medical staff to usher this patient into a contained room or unit to
begin testing and treatment. We’re working to ensure this type of
communication is happening at all levels, but there’s still much room
for improvement on this front.
Health System Execs Respond to the Threat
In an op-ed prepared for the Alliance for Connected Care, Todd J.
Vento, MD, MPH, Intermountain Healthcare’s Medical Director of
Infectious Diseases Telehealth Service; Ethan Booker, MD, Medical
Director of MedStar’s Telehealth Innovation Center; and Lawrence “Rustyâ€
Hofmann, MD, Stanford Health’s Medical Director of Digital Health, made
their pitch for telehealth:
“Telehealth, which has proven to be a very useful tool in
addressing patient needs during flu season, will improve our collective
ability to address COVID-19 if it hits on a larger scale. Telehealth offers several advantages over in-person care in the event of a pandemic.
One key advantage of telehealth is speed,†the three wrote.
“Patients can access clinicians 24/7 without an appointment or physical
trip to the doctor. Using telehealth, our providers in the Stanford
Primary Care team, MedStar Health and Intermountain Healthcare have been
actively evaluating and treating patients with influenza. Current
providers at Stanford Health estimate that almost 50% of patients are
getting oseltamivir (Tamiflu). Because there is no current,
specific medication for Coronavirus, we must be able to advise patients
of reasonable self-directed treatment and surveillance to keep them
home.
Keeping patients at home is a significant advantage of
telehealth. In-home video visits limit community exposure by allowing
patients to avoid contact with other patients in waiting rooms and
direct contact with providers during the exam. Our health systems have
providers who are equipped to work from their own homes, significantly
increasing the safety of providers and bolstering the workforce to
respond to crisis. Workforce readiness in a crisis that may include
such dramatic measures as school and day care closures is a significant
concern for health systems which may be strained to respond. Health
systems are also using telehealth to continue surveillance of patients
already identified as at risk while keeping them at home.
Next, telehealth ensures that treatment in brick-and-mortar
settings is reserved for high-need patients. Moreover, with patients
being seen in their own homes, providers and health systems will be able
to triage and screen exponentially more patients with telehealth vs. an
in-person visit.
Finally, telehealth allows patients who do not have access to
infectious diseases (ID) specialists to access this specialized care
from the small number of experts across the country. When Intermountain
first offered ID telehealth consultation to rural systems throughout the
west, one provider fielded 1,000 consultation requests in the first
fifteen months. To date, the service has provided telehealth care to
over 4,700 patients, 50 percent of whom are over 65 years old.
Each of these advantages illustrate how telehealth can thwart the
spread of COVID-19 and stop it from overwhelming our already stretched
medical system.â€
The three health executive also urged lawmakers to take action to reduce barriers to telehealth that have kept adoption low:
“Congress must act to ensure that seniors – a particularly
vulnerable population generally and for this virus in particular – are
able to receive necessary triage and care through telehealth.
Today, there are restrictions in Medicare that prevent providers
outside of very rural areas from being paid for care provided through
telehealth. As a result, many providers do not offer telehealth services
to seniors. The lack of reimbursement creates a perverse incentive of
encouraging patients to come for in-person care, which will only
overwhelm our health system as well as augment the virus’s spread.
Congress must give the Secretary of Health and Human Services the
ability to waive these restrictions in times of public health
emergencies. As part of the bipartisan, bicameral CONNECT for Health
Act, telehealth champions in Congress foresaw this need and drafted a
provision that would give the Secretary the ability to waive telehealth
restrictions just as he/she would waive Conditions of Participation,
Stark Laws licensure, or other requirements when public health
emergencies are declared.â€
Posted by AGORACOM
at 3:00 PM on Thursday, March 12th, 2020
SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info
These countries are expected to account for virtually all of the legal marijuana sold globally in five years
Marijuana is one of the fastest growing industries on the planet.
Legal weed sales have more than tripled between 2014 and 2018, and
they’re on track to roughly quadruple between the $10.9 billion
generated in licensed cannabis stores 2018 and the projected $40.6 billion in worldwide licensed store sales
by 2024. That’s according to the 2019 “State of the Legal Cannabis
Markets†report released earlier this year by Arcview Market Research
and BDS Analytics.
Yet, what you might find intriguing about this rapid growth is that
it’ll wind up being attributed to just a select few countries. Even
though more than three dozen countries around the world have legalized
medical marijuana, five countries are forecast by Arcview and BDS to
account for $38.2 billion of this aforementioned $40.6 billion in
licensed-store sales by 2024. Note, licensed-store sales doesn’t include
general retailers selling cannabidiol (CBD) products, or
cannabinoid-based drug developers selling pot-derived pharmaceuticals.
1. United States: $30.1 billion in cannabis spending by 2024
As should be no surprise, the U.S. projects as the leading marijuana
market in the world by sales in 2024. In fact, the $30.1 billion in
licensed-store revenue should comprise almost three-quarters of global
licensed sales. According to Arcview and BDS, $9 billion of these sales
are expected to come from the medical side of the equation, up from $4
billion in 2018, with the remaining $21.1 billion derived from
recreational marijuana, up from $5.9 billion last year.
The thing about the U.S. is that cannabis stocks can still thrive even if the federal government doesn’t change its classification of marijuana
from Schedule I. As long as Congress and the president continue to
respect the right of states to make their own choices on cannabis, the
industry could have plenty of runway.
One of the fastest early stage growers looks to be multistate dispensary operator Cresco Labs (OTC:CRLBF).
Cresco, which holds the licenses to more than four dozen retail
locations in 11 states, made a bold move in April when it announced an
all-stock deal to acquire Origin House (OTC:ORHOF).
Origin House is one of only a few companies to hold a cannabis
distribution license in California, the state responsible for a quarter
of all U.S. marijuana spending by 2024. Thus, Cresco Labs’ purchase of
Origin House will give it access to more than 500 Californian
dispensaries, and over 700 nationwide. Cresco and its vertically
integrated peers appear well-positioned to take advantage of this huge
growth opportunity.
2. Canada: $5.18 billion by 2024
Despite being the first industrialized country in the world
to legalize recreational weed, Canada looks to take a distant second to
the United States by 2024 in terms of sales. Arcview and BDS are
projecting that $4.8 billion in sales will come from the recreational
market by then, with the remainder made up of medical cannabis sales.
It’s not uncommon for the medical industry to get cannibalized when
adult-use marijuana is legalized, because it means patients no longer
have to wait for a doctor’s approval and prescription to buy weed.
There’s a lot of competition in Canada right now, so it’s still unclear which company will be Canada’s kingpin. However, Aurora Cannabis (NYSE:ACB) is a relatively good bet to be near the top of the pack solely based on its production potential.
Aurora is already leaps and bounds ahead of its next-closest
competitors with an annual run-rate output of 150,000 kilos as of the
end of March, and plans to be producing at least 625,000 kilos on a
run-rate basis by the end of June 2020. With most of this production
located in Canada, and the company sporting a number of large-scale grow
farms, Aurora Cannabis should be able to take advantage of economies of
scale to drive down its growing costs per gram.
Of course, the real near-term excitement revolves around the upcoming launch of derivative products
(e.g,, edibles, vapes, topicals, concentrates, and infused beverages)
by mid-December. Derivatives have much better margins and pricing power
than dried cannabis flower, which is why Aurora Cannabis and its peers
have been busy beefing up their product offerings over the past year in
preparation for this upcoming launch date.
3. Germany: $1.35 billion by 2024
Even though Arcview and BDS are not expecting Germany to legalize
recreational cannabis, the company’s highly permissive stance toward
medical marijuana, and the fact that health insurers cover medical weed
in the country, should allow sales to soar from $79 million in 2018 to
$1.35 billion by 2024.
Interestingly enough, Canadian cannabis stocks were actually big-time
winners of the German cultivation licensing process. Both Aurora
Cannabis and Aphria (NYSE:APHA) were awarded licenses to grow cannabis in Germany.
For its part, Aphria plans to have an 8,000-square-meter facility in
Germany that’ll begin supplying the country with medical marijuana in
the early part of 2020. In addition to growing cannabis, Aphria
introduced CannRelief in Germany, which is a CBD-based nutraceutical and
cosmetics product line.
As for Aurora Cannabis, its approval to construct a growing facility
will allow the company to supply the German market with 4,000 kilos of
marijuana over four years, with shipments expected to commence October
2020. Of course, this production capacity is liable to be bumped up if
patient demand merits it.
4. Mexico: $1.02 billion by 2024
Arguably one of the oddest “legality†situations concerning marijuana
right now is with Mexico. The nation’s Supreme Court has ruled five
times since 2015 that imposing a ban on recreational cannabis is
unconstitutional. That’s important, because when Mexico’s Supreme Court
reaches five similar decisions on an issue, it becomes the standard throughout the country.
Or, in layman’s terms, the Supreme Court has essentially affirmed the
legality of recreational marijuana and is simply waiting for lawmakers
in the country to hash out the details.
According to Arcview and BDS, Mexico will have legalized adult-use
cannabis by 2024, although the ramp-up of legal sales could be slow. By
2024, recreational weed sales are only expected total $582 million, with
an additional $441 million in medical spending, for a combined $1.02
billion. Mexico’s considerably larger population than Canada makes for
an attractive market opportunity, but it’s unclear how well legal
industries will fare with the noted presence of illicit producers.
One company that hasn’t been shy about its push into Mexico is Medical Marijuana, Inc. (OTC:MJNA), the very first publicly listed pot stock. Southern California-based Medical Marijuana was the first company to import CBD-rich oils
into Mexico in 2016, giving it a head start on building important
relationships with the country’s medical community. You’ll note that
even with recreational legalization likely on the horizon, medical
spending should continue to grow in Mexico. That gives Medical Marijuana
and its RSHO-X hemp oil a real shot to continue penetrating the
Mexico’s medical cannabis market.
5. United Kingdom: $546.9 million by 2024
Although it may not be on track to tip the scales at $1 billion in
sales by 2024, the U.K. is poised to be one of the fastest growing
countries in the world based on cannabis spending. After only $9.9
million in medical spending last year, Britain is forecast for almost
$547 million in medical marijuana revenue by 2024, representing a
compound annual growth rate of 95.2%.
This sudden push to legalize and normalize medical pot use in the U.K. can be partially attributed to the success of GW Pharmaceuticals (NASDAQ:GWPH), the cannabinoid-based drug developer that had the U.S. Food and Drug Administration approve the very first cannabis-derived drug last year.
GW Pharmaceuticals’ CBD-based oral solution known as Epidiolex dazzled
in late-stage studies and wound up reducing seizure frequency for
patients with two rare forms of childhood-onset epilepsy by 30% to 40%.
Additionally, GW Pharmaceuticals’ Sativex, an oromucosal spray
containing both CBD and tetrahydrocannabinol (THC), is approved in more
than a dozen markets in Europe (but not the U.S.).
Britain’s citizens and its government have seen what the U.K.-based
GW Pharmaceuticals can do with cannabinoids, and its government has been
open to the possibility of expanding access to marijuana-based products
for medical patients.
Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends Origin House. The Motley Fool has a disclosure policy.
Posted by AGORACOM
at 12:54 PM on Thursday, March 12th, 2020
SPONSOR: Labrador Gold – Two successful gold explorers lead the way in the Labrador gold rush targeting the under-explored gold potential of the province. Exploration has already outlined district scale gold on two projects, including a 40km strike length of the Florence Lake greenstone belt, one of two greenstone belts covered by the Hopedale Project. Recently acquired 14km of the potential extension of the new discovery by New Found Gold’s Queensway project to the south.Click Here for More Info
Gold is known as the safe-haven asset, and whenever we see a
meltdown in the equity markets or prospects of loose monetary policy,
its price begins to explode to the upside.
Currently, the gold price has a strong negative correlation with the
equity markets meaning when the equity markets fall; investors pour
money into gold and vice versa.
Gold and SPX chart shows negative correlation
The fact is that the current sell-off in the global equity markets is
only a start because there is a lot more to come. After all, the
economic weakness isn’t fully baked into economic data, let alone in
earnings. Thus, there is no better time to buy gold.
Why?
First, the equity markets are in major turmoil as a 1000 point move for the Dow Jones
index has become the norm. Secondly, the Coronavirus has pushed the
Federal Reserve into a corner, and it’s being forced to keep its
monetary policy on the dovish side. The Fed cut the interest rate by 50
basis points only a couple of weeks ago, and yet the market expects
further cuts.
Gold which is up nearly 10% year-to-date
is likely to score serious gain in the coming weeks. The reason is that
we have a situation where monetary policy itself isn’t enough to calm
the markets; however, governments are trying to provide support on the
fiscal front as well. For instance, Donald Trump has pitched the idea of
no payroll tax for this year to soften the blow of Coronavirus. So far,
we have not seen a green flag which is why investors are still nervous.
Donald Trump may achieve some of his goals, but it won’t be enough, the
economic damage is too considerable, and the Coronavirus is still
nowhere close to coming under control.
Going back to the monetary policy action and why there is serious
potential for the gold price to increase; at present, traders and Wall
Street are expecting further interest rate cuts from the Fed during
their meeting next week. An interest rate cut of 50 basis points is the
minimum that investors expect, and according to bigger banks like
Goldman Sachs and JP Morgan, we can expect 75 basis points and a full
percentage point.
Regarding the price action, an interest rate cut isn’t priced in at
all, if it had been, the price would have been trading much higher.
Currently, it’s trading near $1,661.
The Play
If the Fed cuts the interest rate by 50 basis points, this could push
the gold price above 1700 again. Anything more than 50 basis points,
especially a whole percentage point, could pump the price to 1750 or
higher.
The Flow
If we look at the total gold ETF holding data, it supports our thesis
that the gold price is likely to increase because the total holding in
ETFs is sitting at a record level, and the inflow continues to rise. It
appears that investors are discounting this current price weakness and
using this opportunity to buy more.
The chart shows all gold ETFs holding at a record high level
The Bottom Line
The current retracement in the gold price is an enormous opportunity
for traders to get back in the game or add to their position, similar
to the institutions. If for some reason, the Fed doesn’t cut the
interest rates during the meeting, it will create more panic in the
equity markets, which would be a positive sign for the gold price.
Posted by AGORACOM
at 11:35 AM on Thursday, March 12th, 2020
Sponsor: Affinity Metals Corp. (TSX-V: AFF) is a Canadian mineral exploration company building a strong portfolio of mineral projects in North America. The Corporation’s flagship property is the drill ready Regal Property near Revelstoke, BC where Affinity Metals is making preparations for a spring drill program to test two large Z-TEM anomalies. Click Here for More Info
With silver one hundred times cheaper than gold, the
silver-gold-price ratio is close to an all-time high. The obvious trade
is to sell gold and buy silver, says Dominic Frisby. But is that a wise
move?
Silver’s value has plummeted since it stopped officially being money
A friend sent me a screenshot from his phone earlier in the week. It
showed the gold price at $1,666/oz and silver at $16.66/oz. In other
words an ounce of gold is 100 times the price of an ounce of silver. Or,
to use the correct terminology, the gold-silver ratio has gone above
100 – which is almost unheard of.
According to my data, the gold-silver ratio has only ever gone above
100 once before. It didn’t happen in the financial crisis of 2008, the
dotcom crash of 2000, or the Long Term Capital Management Fund Crisis of
1998. It happened in 1991. Silver was $3.50/oz at the time and gold
was, of course, $350. (Actually, it was closer to $370 and the ratio
touched 105).
Apart from 1991 the ratio has never been as high as it was on Monday.
Not once in history. It’s one of the extraordinary extremes that the
coronavirus panic has caused.
The obvious trade here is to sell gold and buy silver. But on the
basis of ratios alone, you should also be selling gold and buying oil,
base metals, stocks, just about anything. To be clear, now is not the
time to be selling gold, particularly with all the fiscal stimulus
that’s coming.
A gold-silver ratio of 15 is but a distant memory
The gold-silver ratio is an odd one. Really, it should be somewhere
around 15. Silver is only 15 times as abundant as gold – there is about
15 times more silver in the earth’s crust as there is gold.
And, historically, the relative price of the two ranged between
around 15 and 20. Until 1875 the USA was a bi-metallic standard – both
silver and gold were money, in other words – and the exchange rate
between the two metals was 15, more or less.
However, in the 20th century, as we all know, countries abandoned
their ties to gold and silver and so money and metal went their separate
ways. That ratio of 15 has become an ever-more distant memory.
It did hit 15 briefly in 1981 as the Hunt Brothers tried to corner
the silver market. But this was an extraordinary situation. It wasn’t
typical. The typical broader trend is that silver is losing its value
relative to gold.
One day we will get back to 15, say the most diehard silver bugs.
This was something I was convinced of in the ardent silver-fanatic days
of my investment youth. I’m not so convinced today.
In fact, you could go one stage further. The gold-silver ratio should
be lower than 15. Silver gets used, gold does not – all the gold that
has ever been mined, pretty much, still exists somewhere. But silver,
with its numerous industrial applications, gets consumed. The ratio
between the two should be closer to ten. And yet here we are with that
ratio ten times higher – and silver ten times too cheap.
The sad fact for silver bugs is that since silver no longer has any
official monetary use, its relative value has plummeted. Some blame
shenanigans on futures exchanges for the low price of silver – I blame
the evolution of money.
Is the world going to go back to some sort of metallic standard as a
result of coronavirus? I doubt it. Money is getting more and more
digital; metal is too physical. But I can see one scenario where it
might.
Get ready for epic debasement
The authorities’ reaction to the crisis will be to debase currency:
slashing rates (we got a dose of that from the Bank of England just this
morning), bailouts, money printing (which will be given some new name
that is even more obfuscatory than quantitative easing), infrastructure
spending (I gather the chancellor is to announce plenty of that in his
Budget later today).
Gold bugs have long been waiting for that loss-of-faith moment when
faith in fiat money will be lost. Might all the monetary manipulation
that is already in place be the long-awaited trigger? The ensuing loss
of faith sees us going back to metal.
It’s a possibility, I suppose, but I think I’m too long in the tooth to see that really happening.
I own some silver. I love silver. I don’t think it’s a bad thing to
be holding in this time of crisis. If it wasn’t so “precious†it would
have been dragged down a lot more – like energy and base metals. It’s
certainly cheap. But so are a lot of other things at the moment.
The gold-silver ratio hit a low at 30 in 2011 when silver touched
$50. It has been in an uptrend ever since. Plenty of us – me included –
have tried to call the top in the ratio and it has kept grinding higher.
The likelihood is that it will pull back a little from the extremes,
perhaps even as far as the 80s. But the reality of our modern fiat age
is that, as far as the gold-silver ratio is concerned, it will take a
fairly extreme change in circumstances for us even to get back to 50. 50
is the new 15.
Sell gold and buy silver as a trade, by all means, but make sure you
reverse the trade – or at least start moving up the stops if we ever get
back to the 80s, 70s or 60s.